Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics and irinotecan therapy.

Kristine K Hahn1, James J Wolff, Jill M Kolesar

  • 1University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WI 53705, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|November 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision oncology's translation gap-Can molecular tumor boards bridge it?

PLoS medicine·2026
Same author

A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.

Frontiers in oncology·2026
Same author

A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.

Cancers·2026
Same author

Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Assessing the Value of Sequential Next-Generation Sequencing and Multiple Molecular Tumor Board Reviews for Patients With Solid-Tumor Malignancies.

JCO precision oncology·2026
Same author

M1 Macrophage-Engineered Vesicles Have Anti-Cancer Activity in Ovarian Cancer.

Cancer nanotechnology·2026

Genetic testing for the UGT1A1*28 variant can identify patients at higher risk for severe side effects from irinotecan. This pharmacogenetic information helps guide treatment decisions for metastatic colorectal cancer.

Area of Science:

  • Pharmacogenetics
  • Oncology
  • Drug Metabolism

Background:

  • Irinotecan is a key treatment for metastatic colorectal cancer.
  • Severe neutropenia and diarrhea are dose-limiting toxicities.
  • Pharmacogenetic research aims to predict patient response and toxicity.

Purpose of the Study:

  • To review irinotecan metabolism and pharmacogenetics.
  • To examine the role of genetic testing in irinotecan therapy.
  • To highlight the UGT1A1*28 polymorphism's impact on irinotecan toxicity.

Main Methods:

  • Review of existing literature on irinotecan pharmacogenetics.
  • Analysis of studies investigating the UGT1A1*28 polymorphism.
  • Examination of updated drug labeling and clinical recommendations.

Related Experiment Videos

Main Results:

  • The UGT1A1*28 genetic variant is a marker for reduced uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) activity.
  • Patients homozygous for UGT1A1*28 face increased risk of severe neutropenia with irinotecan.
  • Interpatient variability in irinotecan pharmacokinetics and toxicity is influenced by genetic factors.

Conclusions:

  • The UGT1A1*28 polymorphism explains variability in irinotecan toxicity.
  • Genetic testing can identify patients at risk for severe neutropenia.
  • Clinicians should consider UGT1A1*28 status for guiding irinotecan dosage adjustments.